RTMS for the Treatment of Post-COVID Associated Affective Symptoms
NCT ID: NCT06716996
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
52 participants
INTERVENTIONAL
2024-11-14
2028-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The overall objective of this randomized, double-blinded study is twofold: First, the investigators will examine the effect of rTMS on post-COVID associated affective symptoms. 52 individuals with post-COVID will be randomized to either receive 20 sessions of rTMS or sham treatment. A detailed psychopathological assessment of the study participants will be performed before and after the completion of rTMS/sham treatment. Secondly, the investigators will perform detailed characterization of the immune system before and after rTMS/sham treatment.
The individual burden and socioeconomic costs of post-COVID-associated neuropsychiatric symptoms are enormous, however, treatment options are limited. The investigators believe that the current proposal will address this key gap in the literature by testing whether rTMS, which constitutes a novel treatment with little side effects, could alleviate these debilitating symptoms. If proven effective, this study could pave the way for a completely new way in which post-COVID conditions are treated.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rTMS
repeated transcranial magnetic stimulation
20 sessions of repeated transcranial magnetic stimulation
sham treatment
sham treatment
20 sessions of sham treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
repeated transcranial magnetic stimulation
20 sessions of repeated transcranial magnetic stimulation
sham treatment
20 sessions of sham treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18-65 years
* Proof of past COVID-19 infection by polymerase chain reaction (PCR) test or serology
* Negative COVID- 19 PCR test at the time of inclusion
* Affective symptoms (≥ 15 points on the Montgomery- Åsberg Depression Rating Scale) lasting for more than 12 weeks since COVID-19 infection
* No psychiatric history prior to the COVID-19 infection
* No major somatic comorbidities or substance use disorder
Exclusion:
* Contraindications to the rTMS treatment e.g. cochlear implants and metallic devices close to the TMS coil, a history of strokes, head injuries or seizures/epilepsy
* Epileptiform potentials in the electroencephalogram (EEG)
* Previous rTMS prior to the study
* Known severe hypersensitivity or severe adverse reaction to rTMS
* Women who are pregnant or breastfeeding
* Intention to become pregnant during the course of the study
* Psychiatric history prior to the COVID-19 infection
* Major somatic comorbidities e.g. renal failure, hepatic dysfunction, heart failure, cardiovascular disease.
* If the participant took antidepressants before the beginning of the study, there needs to be a washout period. The antidepressant has to be stopped for at least 3 weeks before commencing the study.
* The following drugs are not allowed during the study: any antidepressants, any antipsychotics, any drugs that lower the seizure threshold
* Known or suspected non-compliance, drug or alcohol abuse
* Inability to follow the procedures of the study, e.g. due to language problems
* Participation in another study with investigational treatment within the 30 days preceding and during the present study
* Enrolment of the investigator, his/her family members, employees and other dependent persons
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Flurin Cathomas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Flurin Cathomas
PD Dr. med.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Psychiatric University Hospital Zurich
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Flurin Cathomas, PD Dr. med.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMS-CO
Identifier Type: -
Identifier Source: org_study_id